Creabilis SA Report issue

For profit Phase 2
Founded: Luxembourg City Luxembourg (2003)
Status: Acquired by Sienna Biopharmaceuticals (2016)

Organization Overview

First Clinical Trial
2007
NCT01243502
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

ct327 (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Neuralgia (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 1